PCSK9抑制剂依洛尤单抗在降低心血管事件风险中的研究进展

Chinese Journal of Hospital Pharmacy(2020)

Cited 2|Views7
No score
Abstract
2015年,前蛋白转化酶枯草杆菌蛋白酶/kexin 9(proprotein convertase subtilisin kexin 9,PCSK9)抑制剂依洛尤单抗被美国食品药品监督管理局(the Food and Drug Administration,FDA)批准上市,为高脂血症及心血管高危患者的治疗带来了新的希望.本文综述了依洛尤单抗的药学性质及相关临床试验结果,并介绍其在真实世界中的应用效果,以期为临床药物治疗提供参考.
More
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined